TG Therapeutics (NASDAQ:TGTX) Shares Gap Up – Should You Buy?

TG Therapeutics, Inc. (NASDAQ:TGTX) gapped up prior to trading on Tuesday . The stock had previously closed at $27.67, but opened at $29.55. TG Therapeutics shares last traded at $28.99, with a volume of 1,568,539 shares trading hands.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TGTX. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 7th. TD Cowen began coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday. JPMorgan Chase & Co. increased their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. Finally, The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Trading Up 1.5 %

The stock’s 50-day moving average is $31.69 and its 200 day moving average is $25.63. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.73 EPS. On average, research analysts forecast that TG Therapeutics, Inc. will post 0.07 EPS for the current fiscal year.

Insider Activity

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sean A. Power sold 11,337 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares of the company’s stock, valued at $20,313,443.28. This trade represents a 1.66 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,358 shares of company stock valued at $781,497. 10.50% of the stock is currently owned by company insiders.

Institutional Trading of TG Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TGTX. NBC Securities Inc. increased its holdings in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares during the period. Blue Trust Inc. grew its position in TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 849 shares during the last quarter. ORG Wealth Partners LLC acquired a new position in TG Therapeutics in the 3rd quarter valued at $53,000. Values First Advisors Inc. purchased a new position in TG Therapeutics during the 3rd quarter worth $58,000. Finally, GAMMA Investing LLC lifted its stake in shares of TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 2,171 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.